ইঙ্গিত ও ব্যবহার
Rebreath এর জন্য নির্দেশিত:
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
প্রাপ্তবয়স্ক:
The recommended dosage is 175 mcg Revefenacin (one 175 mcg unit‑dose vial) administered by oral inhalation once daily by nebulizer using a mouthpiece. Revefenacin should be administered by the orally inhaled route via a standard jet nebulizer connected to an air compressor. The safety and efficacy of Revefenacin delivered from non-compressor-based nebulizer systems have not been established. The Revefenacin unit-dose vial should only be removed from the foil pouch and opened immediately before use. The vial and any residual content should be discarded after use.Use in Children and Adolescents: Efficacy and safety in children and adolescents under 18 years has not been established.Geriatric Use: Based on available data, no adjustment of the dosage of Revefenacin in geriatric patients is necessary. Renal impairment patient: No dosage adjustment is required for patients with renal impairment.
পার্শ্বপ্রতিক্রিয়া
Common side effects: Cough, runny nose, upper respiratory tract infection, headache.Serious side effects: Glaucoma, eye pain, blurred vision, painful urination, Rash, swelling of face, mouth and tongue.
সতর্কতা ও নিষেধাজ্ঞা
সতর্কতা ও সাবধানতা
Deterioration of Disease and Acute Episodes: Revafir should not be initiated in patients during acutely deteriorating or potentially life-threatening episodes of COPD. Revafir has not been studied in subjects with acutely deteriorating COPD. The initiation of Revafir in this setting is not appropriate.Revafir is intended as a once-daily maintenance treatment for COPD and should not be used for relief of acute symptoms, i.e. as rescue therapy for the treatment of acute episodes of bronchospasm, and extra doses should not be used for that purpose. Acute symptoms should be treated with an inhaled, short-acting beta2-agonist.COPD may deteriorate acutely over a period of hours or chronically over several days or longer. If Revafir no longer controls symptoms of bronchoconstriction, the patient's inhaled, short-acting beta2-agonist becomes less effective, or the patient needs more inhalations of a short-acting beta2-agonist than usual, these may be markers of deterioration of disease. In this setting, a re-evaluation of the patient and the COPD treatment regimen should be undertaken at once. Increasing the daily dose of Revafir beyond the recommended dose is not appropriate in this situation. Paradoxical Bronchospasm: As with other inhaled medicines, Revafir can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with Revafir, it should be treated immediately with an inhaled, short-acting bronchodilator; Revafir should be discontinued immediately and alternative therapy should be instituted.Worsening of Narrow-Angle Glaucoma: Revafir should be used with caution in patients with narrow-angle glaucoma. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g. eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema). Instruct patients to consult a physician immediately if any of these signs or symptoms develops. Worsening of Urinary Retention: Revafir should be used with caution in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of urinary retention (e.g. difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to consult a healthcare provider immediately if any of these signs or symptoms develops. Immediate Hypersensitivity Reactions: Immediate hypersensitivity reactions may occur after administration of Revafir. If such a reaction occurs, therapy with Revafir should be stopped at once and alternative treatments should be considered.
নিষেধাজ্ঞা
Revefenacin is contraindicated in patients with hypersensitivity to Revefenacin or any component of this product.